BMS-1001

CAS No. 2113650-03-4

BMS-1001( BMS 1001 | BMS1001 )

Catalog No. M13359 CAS No. 2113650-03-4

A potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 181 In Stock
5MG 126 In Stock
10MG 187 In Stock
25MG 316 In Stock
50MG 437 In Stock
100MG 607 In Stock
200MG 817 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BMS-1001
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.
  • Description
    A potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    BMS 1001 | BMS1001
  • Pathway
    Immunology/Inflammation
  • Target
    PD-1/PD-L1
  • Recptor
    PD-1/PD-L1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2113650-03-4
  • Formula Weight
    631.122
  • Molecular Formula
    C35H35ClN2O7
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    (2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-5-methylbenzyl)-D-serine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Guzik K, et al. J Med Chem. 2017 Jul 13;60(13):5857-5867. 2. Chupak, L.S., and Zheng, X. Compounds useful as immunomodulators. PCT/US2014/053695, (2015).
molnova catalog
related products
  • (D)-PPA 1

    PD-1/PD-L1 interaction inhibitor. Binds to PD-L1 (Kd = 0.51 μM). Inhibits interaction at 1 mg/mL in flow cytometry. Inhibits tumor growth and prolongs survival time of mice in vivo.

  • Tislelizumab

    Tislelizumab (BGB-A317) is an IgG4 class monoclonal antibody targeting human programmed death receptor-1 (PD-1) with antitumor activity that inhibits the binding of Fcγ receptor to macrophages and can be used to study advanced squamous non-small cell lung cancer.

  • Avelumab

    Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.